secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001104659-22-002543
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa reports ~$182M year-end cash sufficient into 2024; mavrilimumab Phase 3 fails; pipeline updates
--------------------------------------------------------------------------------

- Preliminary year-end 2021 cash, cash equivalents and short-term investments of ~$182M (unaudited), expected to fund operations into 2024.
- Mavrilimumab Phase 3 in COVID-19 ARDS did not meet primary endpoint; company evaluating next steps.
- Full-year 2022 ARCALYST net revenue guidance to be provided with Q4 and full-year 2021 financial results.
- Vixarelimab Phase 2b data in prurigo nodularis expected in second half of 2022.
- KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922002543/0001104659-22-002543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922002543/tm222297d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-002543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer